During Antioxidants 2014 World Congress, Dr David Devos, from University of Lille Nord, France will give a presentation about the first clinical evidence about the neuroprotective potential of a therapeutically safe chelation treatment on early- stage Parkinson’s patients that were already stabilized for dopamine and responded significantly to treatment in both brain iron deposits and indicators of disease progression.
The novel treatment relied on oral administration of deferiprone that by chelation of labile iron it conferred upon oxidation-stressed animals increased striatal-dopamine levels and improved motor functions, while essentially sparing systemic iron. The paradigmatic modality of chelation with deferiprone in Parkinson’s disease should prompt multi-center studies in various disorders of regional iron accumulation or misdistribution.
If you would like to know more about targeting chelatable iron as a therapeutic option in the treatment of Parkinson’s disease, come and join us to Antioxidants World Congress 2014.
For more details: www.isanh.fr
Share this post
Please click here to purchase
